Filing Flows › Aurinia Pharmaceuticals (AUPH) › Q2 2026 › vs Q2 2025
Aurinia Pharmaceuticals (AUPH) Q2 2026 vs Q2 2025 (year over year)
Aurinia Pharmaceuticals's revenue rose $13.2M (+19%) from $70.0M in Q2 2025 to $83.2M in Q2 2026. The biggest changes: Net product sales +$12.8M (+19%); License, collaboration and royalty revenue +$374K (+11%). Operating margin 55.7% against 28.7% (+27.0 pts).
Aurinia Pharmaceuticals, Q2 2026: revenue $83.2M (+19% year over year), operating margin 55.7%, net earnings $37.4M, operating cash flow $52.6M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Operating margin | 55.7% | 28.7% | +27.0 pts |
| Net margin | 45.0% | 30.7% | +14.2 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Net product sales | $79.4M | $66.6M | $12.8M | +19% |
| License, collaboration and royalty revenue | $3.8M | $3.4M | $374K | +11% |
| Revenue | $83.2M | $70.0M | $13.2M | +19% |
| Other income, net | $2.4M | $2.1M | $372K | +18% |
| Operating profit | $46.3M | $20.1M | $26.3M | +131% |
| Costs & expenses | $36.9M | $49.9M | −$13.0M | -26% |
| Pre-tax earnings | $48.8M | $22.2M | $26.6M | +120% |
| Net earnings | $37.4M | $21.5M | $15.9M | +74% |
| Income tax | $11.4M | $643K | $10.7M | 18× |
| Depreciation & amortization | $4.8M | $4.9M | −$30K | -0.6% |
| Share-based compensation | $2.8M | $5.4M | −$2.6M | -48% |
| Working capital & other | $7.5M | $12.4M | −$4.9M | -40% |
| Operating cash flow | $52.6M | $44.2M | $8.3M | +19% |
Questions
How much did Aurinia Pharmaceuticals's revenue grow year over year in Q2 2026?
Aurinia Pharmaceuticals's revenue rose $13.2M (+19%) from $70.0M in Q2 2025 to $83.2M in Q2 2026.
What drove Aurinia Pharmaceuticals's revenue change in Q2 2026?
Net product sales +$12.8M (+19%); License, collaboration and royalty revenue +$374K (+11%).